Decision Support Service

Concepts

• system and support
• decision support service
• decision support contract
• interpretation services
• the rare disease decision support service contract
• a rare disease decision support software solution
• the nhs genomic medicine service
• ("decision support contract
• genomics england
• november

Location

London:

Description

The provision of a Rare Disease Decision Support software solution for NGIS

Total Quantity or Scope

In November 2018 Genomics England signed a contract with Congenica for the provision of interpretation services to support the NHS Genomic Medicine Service ("GMS") ("Decision Support Contract") which is due to expire on 30 November 2024 A contract amendment for the Rare Disease Decision Support Service contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months.

Award Detail

Renewal Options

Options to extend the term for a further 6 + 6 months.

CPV Codes

• 72250000 - System and support services

Indicators

• Options are available.

Legal Justification

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Genomics England will on 1 December 2024 enter into a contract amendment for the Decision Support Service Contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months with an option to extend for a further 6 + 6 months. Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract. NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System (NGIS) pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. Genomics England are in the process of developing a replacement solution.